Adeno-Associated Virus Vector-Based Gene Therapy Market 2034

Market Outlook According to Expert Market Research , the global adeno-associated virus (AAV) vector-based gene therapy market is poised for exceptional growth, projected to expand at a CAGR of 32.93% between 2025 and 2034. This robust growth is fueled by increasing investments in biotechnology, a sharp focus on technological advancements in healthcare, and a growing number of clinical trials that are driving the adoption of AAV-based gene delivery systems. Gene therapy, once a futuristic concept, is now revolutionizing the treatment of genetic disorders, cancers, and chronic illnesses, with AAV vectors emerging as the preferred vehicles for safe and efficient gene transfer. Introduction to AAV Vector-Based Gene Therapy Understanding AAV Vectors in Gene Therapy AAV vectors are engineered viruses derived from the adeno-associated virus, a non-pathogenic virus that has gained attention for its low immunogenicity and ability to deliver genes precisely. These characteristics make AAV vector...